-
Mipomersen (INN;
trade name Kynamro) is a drug used to
treat homozygous familial hypercholesterolemia and is
administered by
subcutaneous injection. There...
- targets. In 2008, Isis and
Genzyme entered into a
partnered drug
candidate mipomersen (Kynamro),
intended to
treat homozygous familial hypercholesterolemia...
- Corporation, is
administered via
subcutaneous injection in the form of a
mipomersen sodium solution. The
chemical structure is
composed of a 20-nucleotide...
-
example of
using an
asRNA as a
therapeutic agent is
mipomersen,
which was
approved by FDA in 2013.
Mipomersen was
developed to
manage the
level of low-density...
-
phosphorothioate antisense oligonucleotides fomivirsen (Vitravene) and
mipomersen (Kynamro) for
human therapeutic use. In virology, the term "sense" has...
- e.g., the
drugs fomivirsen (Vitravene), oblimersen, alicaforsen, and
mipomersen (Kynamro).
Further examples of
these include:
Diazinon Fenitrothion Fenthion...
-
familial hypercholesterolemia. In
January 2013, The US FDA also
approved mipomersen,
which inhibits the
action of the gene
apolipoprotein B, for the treatment...
- a
novel antioxidant,
failed a phase-III trial. Apoprotein-B
inhibitor mipomersen (approved by the FDA in 2013
homozygous familial hypercholesterolemia...
-
treatment of
familial chylomicronaemia syndrome in May 2019. In
January 2013
mipomersen (marketed as Kynamro) was
approved by the FDA for the
treatment of homozygous...
- (Desirudin), for atherothrombosis, Now
owned by
Bausch Health.
Kynamro (
Mipomersen), an
antisense drug
invented by Isis
Pharmaceuticals and
acquired by Genzyme...
